[Sneddon-Wilkinson disease: efficacy of intermittent adalimumab therapy after lost response to infliximab and etanercept].

Abstract

BACKGROUND:

Sneddon-Wilkinson disease (SWD) is a rare chronic neutrophilic dermatosis. The first-line treatment is dapsone but resistance to treatment may sometimes pose a challenge.

CASE REPORT:

We report a multidrug-resistant patient who responded dramatically before gradually losing response to infliximab and then etanercept. Complete remission was again obtained with adalimumab.

DISCUSSION:

Our case confirms the previously reported dramatic efficacy of anti-TNF biological agents in recalcitrant SWD but highlights the possibility of subsequent loss of response. Furthermore, it illustrates the efficacy of adalimumab in this indication.

• Authors: M Versini, F Mantoux, K Angeli, T Passeron, J-P Lacour
• Journal: Annales de dermatologie et de venereologie (Ann Dermatol Venereol) Vol. 140 Issue 12 Pg. 797-800 (Dec 2013) ISSN: 0151-9638 [Print] France
• Vernacular Title: Maladie de Sneddon-Wilkinson échappant à l'infliximab et à l'étanercept: efficacité de l'adalimumab.
• PMID: 24315227 (Publication Type: Case Reports, English Abstract, Journal Article)
• Copyright: Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Chemical References

• Anti-Inflammatory Agents
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Immunoglobulin A
• Immunoglobulin G
• Immunosuppressive Agents
• Receptors, Tumor Necrosis Factor
• Tumor Necrosis Factor-alpha
• Infliximab
• Adalimumab
• Etanercept

Topics

• Adalimumab
• Aged
• Anti-Inflammatory Agents (pharmacology, therapeutic use)
• Antibodies, Monoclonal (pharmacology, therapeutic use)
• Antibodies, Monoclonal, Humanized (pharmacology, therapeutic use)
• Drug Administration Schedule
• Drug Resistance
• Drug Substitution
• Etanercept
• Humans
• Immunoglobulin A (blood)
• Immunoglobulin G (pharmacology, therapeutic use)
• Immunosuppressive Agents (pharmacology, therapeutic use)
• Infliximab
• Male
• Monoclonal Gammopathy of Undetermined Significance (complications)
• Neutrophil Infiltration
• PUVA Therapy
• Receptors, Tumor Necrosis Factor (therapeutic use)
• Skin Diseases, Vesiculobullous (complications, drug therapy, immunology, pathology)
• Tumor Necrosis Factor-alpha (antagonists & inhibitors)